Clinical Trials Logo

Filter by:
NCT ID: NCT05173844 Recruiting - Clinical trials for Cognitive Impairment

Digital Sleep Therapy for Older Adults With Cognitive Impairment

ExCEED
Start date: November 10, 2022
Phase: N/A
Study type: Interventional

This study aims to determine the efficacy of digital Behavioural Therapy for Insomnia (dBTi) compared to online sleep health education (control) at reducing insomnia symptom severity (Insomnia Severity Index: ISI) in older adults (50+ years) with subjective cognitive impairment from baseline compared to week 8.

NCT ID: NCT05172960 Recruiting - Clinical trials for Aortic Stenosis, Severe

ALLIANCE: Safety and Effectiveness of the SAPIEN X4 Transcatheter Heart Valve

Start date: June 20, 2022
Phase: N/A
Study type: Interventional

The objective of this study is to establish the safety and effectiveness of the Edwards SAPIEN X4 Transcatheter Heart Valve (THV) in subjects with symptomatic, severe, calcific aortic stenosis (AS).

NCT ID: NCT05172596 Active, not recruiting - Multiple Myeloma Clinical Trials

PHE885 CAR-T Therapy in Adult Participants With Relapsed and Refractory Multiple Myeloma

Start date: March 7, 2022
Phase: Phase 2
Study type: Interventional

This is a Phase II study to determine the efficacy and safety of PHE885, a BCMA-directed CAR-T cell therapy, manufactured with a new process. The CAR-T cell therapy will be investigated as a single agent in relapsed and refractory multiple myeloma

NCT ID: NCT05171855 Active, not recruiting - Clinical trials for Endocrine System Diseases

A Trial to Investigate Long Term Efficacy and Safety of Lonapegsomatropin in Adults With Growth Hormone Deficiency

Start date: December 16, 2021
Phase: Phase 3
Study type: Interventional

This is a phase 3 open-label multicenter extension study designed to evaluate the long-term safety and efficacy of Lonapegsomatropin administered once-weekly. The study participants are adults (males and females) with confirmed growth hormone deficiency (GHD) having completed the treatment period in study TCH-306 (foresiGHt).

NCT ID: NCT05171075 Recruiting - Pulmonary Embolism Clinical Trials

A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE

MAGNOLIA
Start date: September 27, 2022
Phase: Phase 3
Study type: Interventional

This is a Phase 3, multicenter, open-label, blinded endpoint study to evaluate the effect of abelacimab relative to dalteparin on venous thromboembolism (VTE) recurrence and bleeding in patients with gastrointestinal (GI)/genitourinary (GU) cancer associated VTE (Magnolia)

NCT ID: NCT05171049 Recruiting - Pulmonary Embolism Clinical Trials

A Study Comparing Abelacimab to Apixaban in the Treatment of Cancer-associated VTE

ASTER
Start date: May 5, 2022
Phase: Phase 3
Study type: Interventional

This is a Phase 3,multicenter, randomized, open-label, blinded endpoint evaluation study comparing the effect of abelacimab relative to apixaban on venous thromboembolism (VTE) recurrence and bleeding in patients with cancer associated VTE (ASTER)

NCT ID: NCT05170204 Recruiting - Clinical trials for Non-Small Cell Lung Cancer

A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC)

Start date: November 1, 2022
Phase: Phase 3
Study type: Interventional

This study will evaluate the efficacy and safety of multiple therapies in participants with locally advanced, unresectable, Stage III NSCLC with eligible biomarker status as determined by Version 8 of the American Joint Committee on Cancer/Union for International Cancer Control NSCLC staging system.

NCT ID: NCT05169697 Recruiting - Clinical trials for Advanced Solid Tumor

A Study to Assess YH002 in Combination With YH001 in Subjects With Advanced Solid Tumors

Start date: February 21, 2022
Phase: Phase 1
Study type: Interventional

A multicenter, open-label, phase I dose escalation study to evaluate the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of YH002 in combination with YH001 in subjects with advanced solid tumors

NCT ID: NCT05169333 Recruiting - Clinical trials for Cardiovascular Diseases

The Oxford Risk Factors And Non-Invasive Imaging Study

ORFAN
Start date: February 23, 2016
Phase:
Study type: Observational [Patient Registry]

ORFAN is a prospective, multi-centre, multi-ethnic cohort observational study collecting CT scans, biological material and outcomes data, to develop and validate novel biomarkers of cardiometabolic and other disease risk.

NCT ID: NCT05169177 Recruiting - Liver Neoplasm Clinical Trials

Radio-opaque Contrast Agents for Liver Cancer Targeting With KIM During Radiation Therapy

ROCK-RT
Start date: October 17, 2022
Phase:
Study type: Observational

This observational study will investigate the properties of image files standardly collected during radiation therapy treatment in a cross-section of liver cancer patients who received stereotactic ablative body radiation therapy (SABR) after trans-catheter arterial chemo emobilisation (TACE). Specifically, it will determine whether the radio-opaque contrast agents in the image files can be detected by tumour-tracking software (KIM).